<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03967275</url>
  </required_header>
  <id_info>
    <org_study_id>EGN_2018_11</org_study_id>
    <nct_id>NCT03967275</nct_id>
  </id_info>
  <brief_title>Subconjunctival Injection of Allogeneic Mesenchymal Stem Cells in Severe Ocular Chemical Burn</brief_title>
  <acronym>SyMbOL</acronym>
  <official_title>Subconjunctival Injection of Allogeneic Mesenchymal Stem Cells in Severe Ocular Chemical Burn SyMbOL Pre Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this pre-clinical study is to demonstrate the robustness of Bone Marrow
      derived Mesenchymal Stem Cells (BM-MSC) production, to treat patients with severe eye burns.

      For bone marrow donors who agree to participate, a 10 ml BM sample will be collected apart
      the 1 liter BM dedicated to transplantation.

      A maximum of three donors of allogeneic BM-MSCs will be included. A ready-to-use BM-MSC
      suspension will be produced and stored for 10 years to accumulate data about stability of
      cryopreserved cells.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">March 2030</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The number of donors needed to obtain 3 BM harvest.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">3</enrollment>
  <condition>Bone Marrow Donor</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>bone marrow harvest</intervention_name>
    <description>During bone marrow harvest, an additional 10 mL sample will be collected for the study.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Bone marrow donors
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

        - Patient with a bone marrow donation planned

        Exclusion criteria:

          -  The donor is finally not eligible

          -  The harvest cannot be performed

          -  The sample cannot be obtained during the BM harvest procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eric Gabison</last_name>
    <phone>+33148036484</phone>
    <email>egabison@for.paris</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Am√©lie Yavchitz</last_name>
    <phone>+33148036454</phone>
    <email>ayavchitz@for.paris</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Saint Louis Hospital, APHP</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Camille MAHEUX</last_name>
      <email>camille.maheux@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 26, 2019</study_first_submitted>
  <study_first_submitted_qc>May 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2019</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bone marrow harvest</keyword>
  <keyword>Bone Marrow derived Mesenchymal Stem Cells (BM-MSC)</keyword>
  <keyword>Pre-clinical</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burns, Chemical</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

